Free Trial
NASDAQ:TSBX

Turnstone Biologics Q4 2023 Earnings Report

Turnstone Biologics logo
$0.32 -0.02 (-6.43%)
Closing price 03:58 PM Eastern
Extended Trading
$0.33 +0.01 (+2.41%)
As of 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Turnstone Biologics EPS Results

Actual EPS
-$0.73
Consensus EPS
-$0.86
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Turnstone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Turnstone Biologics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 21, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Turnstone Biologics' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Turnstone Biologics Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year
See More Turnstone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Turnstone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Turnstone Biologics and other key companies, straight to your email.

About Turnstone Biologics

Turnstone Biologics (NASDAQ:TSBX), a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

View Turnstone Biologics Profile

More Earnings Resources from MarketBeat